| |
| |
|
| Insider
Information: |
Levin Mark J |
| Relationship: |
10% Owner |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
42,729,845 |
|
|
Indirect Shares
|
23,401,954 |
|
|
| Direct
Value |
$202,607,494 |
|
|
|
Indirect Value
|
$645,566,423 |
|
|
| Total
Shares |
66,131,799 |
|
|
| Total
Value |
$848,173,917 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
8
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
8
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-8.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -215.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Millennium Pharmaceuticals Inc |
MLNM |
Director |
2008-05-09 |
0 |
2008-04-18 |
405,895 |
Premium* |
|
|
Foundation Medicine, Inc. |
FMI |
Director, 10% Owner |
2014-05-12 |
17,462 |
2014-05-12 |
0 |
Premium* |
|
|
Carisma Therapeutics Inc |
CARM |
Director, 10% Owner |
2014-02-11 |
4,841,591 |
2014-02-05 |
330,708 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
10% Owner |
2014-06-24 |
5,602,045 |
2014-06-24 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
10% Owner |
2014-07-23 |
11,681,008 |
|
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
Director, 10% Owner |
2018-09-19 |
33,029 |
2018-09-19 |
6,394,845 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
10% Owner |
2017-03-16 |
111,244 |
2017-03-16 |
3,453,753 |
Premium* |
|
|
Neon Therapeutics, Inc. |
NTGN |
10% Owner |
2018-06-29 |
9,741,636 |
2018-06-29 |
0 |
Premium* |
|
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2018-08-30 |
3,278,752 |
2018-08-30 |
0 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
Director, 10% Owner |
2021-11-10 |
75,800 |
2021-11-10 |
3,970,625 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
10% Owner |
2021-09-15 |
3,549,881 |
2021-09-15 |
3,048,780 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2021-06-04 |
374,848 |
2021-06-04 |
5,536,956 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-06 |
3,422,549 |
2021-05-06 |
260,392 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
101 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CARM |
Carisma Therapeutics Inc |
Director |
– • – |
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
330,708 |
|
- |
|
| SAGE |
Sage Therapeutics, Inc. |
10% Owner |
– – • |
2014-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
476,189 |
|
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • – |
2015-11-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
472,941 |
|
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
Director |
– • • |
2019-07-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
285,714 |
|
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2008-04-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
400,000 |
2,264,224 |
0 |
- |
|
| MLNM |
Millennium Pharmaceutical... |
Director |
– • – |
2008-04-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
400,000 |
400,000 |
0 |
- |
|
| FMI |
Foundation Medicine, Inc. |
Director |
– • – |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
6,219,645 |
6,569,645 |
0 |
- |
|
| CARM |
Carisma Therapeutics Inc |
Director |
– • • |
2014-02-11 |
4 |
B |
$0.00 |
$0 |
D/D |
551,482 |
4,841,591 |
3.84 |
- |
|
| FMI |
Foundation Medicine, Inc. |
Director |
– • • |
2014-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
17,462 |
17,462 |
0 |
- |
|
| FMI |
Foundation Medicine, Inc. |
Director |
– • • |
2014-05-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,762,988) |
0 |
0 |
- |
|
| FMI |
Foundation Medicine, Inc. |
Director |
– • • |
2014-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
120,577 |
120,577 |
0 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
10% Owner |
– – • |
2014-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,602,045 |
5,602,045 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
10% Owner |
– – • |
2014-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
11,204,819 |
11,681,008 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • – |
2015-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
10,588,235 |
11,061,176 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • • |
2016-12-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(750,000) |
10,311,176 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • • |
2017-04-12 |
4 |
AS |
$0.00 |
$0 |
I/I |
(920,000) |
9,391,176 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • • |
2018-06-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,500,000) |
7,891,176 |
0 |
- |
|
| NTGN |
Neon Therapeutics, Inc. |
10% Owner |
– – • |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,341,636 |
9,741,636 |
0 |
- |
|
| RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
– – • |
2018-08-30 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
2,981,437 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Director |
– • • |
2018-09-19 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,500,000) |
6,391,176 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
Director |
– • • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
5,595,238 |
5,880,952 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2020-11-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,000,000) |
9,230,349 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2020-12-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,000,000) |
7,024,031 |
0 |
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
– – • |
2021-02-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(914,216) |
4,508,333 |
0 |
- |
|
| RVMD |
Revolution Medicines, Inc... |
10% Owner |
– – • |
2021-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,500,000) |
5,524,031 |
0 |
- |
|
101 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
